Background E-cigarette, or Vaping, Product Use–Associated Lung Injury (EVALI) is a complex inflammatory syndrome predominantly seen in adolescents and young adults. The clinical and laboratory profile can easily mimic infectious and non-infectious conditions. The exclusion of these conditions is essential to establish the diagnosis. Recently, the novel coronavirus disease 2019 (COVID-19) pandemic introduced the multisystem inflammatory syndrome in children (MIS-C). MIS-C knowledge is evolving. The current criteria to establish the diagnosis are not specific and have overlapping features with EVALI, making the accurate diagnosis a clinical challenge during continued COVID-19 transmission within the community. Case Report Three young adults evaluated at our emergency department for prolonged fever, gastrointestinal and respiratory complaints that initially assessed for possible MIS-C due to epidemiological links to COVID-19, and eventually were diagnosed with EVALI. The clinical, laboratory and radiological characteristics of both entities are explored, as well as the appropriate medical management. Why Should an Emergency Physician Be Aware of This? : Physician awareness of overlapping and differentiating EVALI and MIS-C features is essential to direct appropriate diagnostic evaluation and medical management of adolescents and young adults presenting with systemic inflammatory response during the unfolding pandemic of COVID-19.
Vaping Associated Lung Injury During COVID-19 Multisystem Inflammatory Syndrome Outbreak